Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease
Jing Fu(Columbia University Irving Medical Center), Suzanne Lentzsch(UPMC Hillman Cancer Center)
Cited by 73
Related Papers
Targeting the Microtubular Network as a New Antimyeloma Strategy
|Molecular Cancer Therapeutics|2011|28
The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
|Nature Communications|2023|19